PAGE 11 — WHAT MUST CHANGE: FINDINGS AND RECOMMENDATIONS

What Must Change: Findings and Recommendations

The recommendations on this page are derived from the research report on which this site is based. They are the authors' conclusions from the evidence — normative in character, grounded in documented fact, and directed at specific institutions with the capacity to act.

11.1 Summary of Findings

This site's central finding is that spouses and partners of ADF veterans administered mefloquine and tafenoquine during the East Timor and Bougainville deployments of 1998 to 2002 are an unacknowledged casualty population.

The harm they have sustained is not incidental to the drug trial story. It is a foreseeable, documented, and institutionally neglected consequence of the decision to administer potent neurotoxic compounds to service personnel without adequate informed consent, without appropriate monitoring, and without follow-up care.

The specific findings supporting this conclusion are as follows.

One. There is a plausible and evidence-grounded neurobiological mechanism by which quinoline toxicity produces behavioural changes — including paranoia, dissociative rage, emotional disinhibition, and personality change — that constitute domestic violence risk. This mechanism is consistent with established neuroanatomy and with the specific adverse effects formally listed for both drugs.

Two. The behavioural patterns associated with quinoline neurotoxicity are documented in the peer-reviewed and regulatory literature and are consistent with patterns reported by partners of affected ADF veterans.

Three. The near-universal misdiagnosis of quinoline toxicity as PTSD has elevated domestic harm risk by directing treatment away from the neurological substrate of dangerous behaviour and toward frameworks inappropriate to the injury.

Four. The long-term harm experienced by spouses — including chronic trauma, nervous system dysregulation, financial devastation, social isolation, loss of children, and lifelong health consequences — constitutes a serious and unrecognised public health burden with a traceable institutional cause.

Five. Every relevant institution — DVA, Defence, the domestic violence service system, the family law system, the criminal law system — currently lacks the framework, the training, and the legal categories to appropriately recognise or respond to the secondary harm experienced by these women.

Six. The Australian government bears a specific and legally arguable duty of care toward the families of clinical trial subjects, which has not been acknowledged or discharged.

Seven. The absence of a large documented case series reflects institutional inattention and the absence of an investigative framework, not a small problem. The cases exist. The mechanisms for finding and recording them do not.

11.2 Recommendations

A — Formal Recognition

The Australian government must formally acknowledge that spouses and partners of ADF quinoline trial subjects are a secondary harm population, and that the domestic violence, relational breakdown, and associated health consequences experienced in these families are a foreseeable consequence of the government drug trial conducted on their partners.

Formal recognition is the precondition for everything that follows. Without it, every downstream reform lacks the foundational acknowledgement that makes support legitimate and entitlements justifiable.

B — A Dedicated Support Program

A dedicated support program for the spouses and families of ADF quinoline veterans must be established, independent of DVA and Defence, and developed in genuine consultation with those affected. The program must address: psychological and neurological support for partners with acquired trauma; financial support to address the costs generated by the veteran's medical and legal crises; legal support in family court and criminal proceedings; social support and reconnection for isolated partners; and child-focused support acknowledging the developmental consequences of growing up in an affected household.

Independence from DVA and Defence is essential. The institutions that failed these families cannot be the primary architects of their support.

C — Training for Domestic Violence Services

The domestic violence sector must receive specific training and guidance on quinoline-related neurotoxicity, enabling practitioners to recognise the distinctive features of this presentation, apply appropriate safety planning, and connect affected families with relevant neurological and support services. This training should be developed in partnership with neurotoxicology expertise and with input from affected partners.

D — Legal System Reform

The family law system and the criminal law system require judicial education and expert guidance frameworks that incorporate quinoline toxicity as a recognised neurological context relevant to assessing domestic violence risk, parenting capacity, and criminal responsibility. Forensic psychiatric practice guidelines should be developed to address the mefloquine intoxication syndrome as a clinically and legally significant finding.

E — Coroner Reform

Coroners investigating deaths — suicides, homicides, and family violence fatalities — in ADF veteran families must be required, as a standard step in any investigation involving veterans from quinoline deployment eras, to obtain and examine the veteran's pharmaceutical record from AMI and ADF sources. This single reform would begin to create the case documentation that currently does not exist.

F — Independent Research

The Australian government must commission independent longitudinal research specifically examining domestic violence and family harm outcomes in the cohort of ADF quinoline veterans and their families. This research must be conducted by investigators with expertise in neurotoxicology, domestic violence, and veteran health. It must include the perspectives of affected partners. It must be genuinely independent of Defence and DVA.

G — Legislative Amendment

The Veterans' Entitlements Act and the Military Rehabilitation and Compensation Act must be amended to create a category of secondary casualty for family members of ADF clinical trial subjects who have sustained harm as a foreseeable consequence of those trials.

11.3 The Royal Commission Baseline and What Remains

The Royal Commission into Defence and Veteran Suicide's 2024 findings on mefloquine and tafenoquine represent the first official acknowledgement at that level that these drugs caused harm to Australian veterans and that the institutional response was inadequate. The government's acceptance in principle of the brain injury program recommendation is a significant step.

The recommendations above build on that foundation. They do not replace it.

The Royal Commission's chapter addressed veterans. These recommendations address the families — specifically the partners — who have carried their own share of the consequences of the same institutional decisions.

The brain injury program for veterans, when established, will be necessary but not sufficient. It will not, as currently proposed, extend recognition to spouses. It will not address the domestic violence service gap. It will not reform the family law or criminal law frameworks. It will not create the legislative category of secondary casualty.

These recommendations ask for what the Royal Commission did not: that the family be recognised as within the scope of institutional responsibility, and that the harm to partners be treated as what it is — a public health consequence of a government decision, owed a government response.